

# **16th Dresden Symposium on Autoantibodies**

**Achievements and Challenges in Research, Diagnostics and Therapy  
of Autoimmune Diseases**

**Dresden, September 12-15, 2023**

**7<sup>th</sup> International Consensus on ANA Pattern (ICAP) Workshop  
and Workshop on Harmonization of Autoantibody Detection**

**September 11, 2023**

**Congress venue:**

**Dresden Fair (Messe Dresden), Messering 6,  
Portal (Tor) 2, 01067 Dresden**

## **Pre-final Program**

MONDAY  
SEPTEMBER 11

## 7<sup>th</sup> International Consensus on ANA Pattern (ICAP) Workshop

Co-Chairs: Luis E.C. Andrade (São Paulo, Brazil)  
Manfred Herold (Innsbruck, Austria)

### 10.30-12.30

### 7<sup>th</sup> ICAP WORKSHOP PART I

- |             |   |
|-------------|---|
| 10.30-10.35 | Welcome and agenda  |
| 10.35-10.40 | Nomination of Alan Wiik as ICAP honorary member   |
| 10.40-11.00 | Detection of antinuclear antibodies: recommendations from EFLM, EASI and ICAP<br><i>Carolien Bonroy (Ghent, Belgium) and Martine Vercammen (Bruges, Belgium)</i>  |
| 11.00-11.15 | Adopting the International Consensus on ANA Patterns (ICAP) classification for reporting: the experience of the Italian clinical laboratories<br><i>Maria Infantino (Florence, Italy)</i>   |
| 11.15-11.25 | Antinuclear Antibody-HEp-2 IIF Competency Assessment Programme of Society for Clinical Microbiologists of Türkiye: Analysis of Five-Year Results<br><i>Nilgun Kasifoglu, <u>Neval Yurttutan Uyar</u>, Ekrem Yasar, Nese Kaklikkaya, Tutku Taskinoglu, Burcin Sener (Eskisehir, Istanbul, Diyarbakir, Trabzon &amp; Ankara, Türkiye)</i> |
| 11.25-11.45 | Heterogeneity in HEp-2 IFA pattern reporting and frequency worldwide - The HEp-2 CIC project<br><i>Trischna Martins Berger (Berlin, Germany), on behalf of the HEp-2 CIC project team</i>   |
| 11.45-12.05 | How consistent are the associations of HEp-2 IFA pattern and autoantibody specificities<br><i>Diana Landoni (Montevideo, Uruguay)</i>   |
| 12.05-12.20 | Novel relevant autoantibodies and their HEp-2 IFA pattern association<br><i>Jan Damoiseaux (Maastricht, The Netherlands)</i>  |
| 12.20-12.30 | The ICAP App for cell phone<br><i>Wilson de Melo Cruvinel (Goiânia, Brazil)</i>   |
| 12.30-13.30 | LUNCH BREAK   |

13.30-15.00

## 7th ICAP WORKSHOP PART II

13.30-13.45

Harmonization of ANA testing challenge: quantification strategy to accurately predict end-point titers avoiding serial dilution  
*Teresa Carbone, Vito Pafundi, Vito Ciardo, Maria Infantino, Salvatore D'Angelo (Potenza, Italy)*

13.45-14.15

Is ICAP ready to acknowledge and recommend the split of AC-2 pattern into AC-2a (bona fide DFS pattern) and AC-2b ("pseudo-DFS pattern")? PROS AND CONS debate

14.15-14.40

Exploring the limits in HEp-2 IFA pattern definition

- Low intensity fluorescence
- Limitations in the definition of inter-related patterns (AC-6/AC-7; AC/8/AC-9/AC-10; AC-11/AC-12)
- Patterns that do not fit into ICAP classification algorithm (mixed patterns, unclassified patterns) – how can we move forward?

14.40-15.00

ICAP's future projects

15.00-15.30

COFFEE BREAK

## Harmonization of Autoantibody Determination

Co-Chairs: Ulrich Sack (Leipzig, Germany)  
Martin Blüthner (Karlsruhe, Germany)

15.30-15.50

The need for harmonization in relation to the classification criteria  
*Lieve Van Hoovels (Aalst, Belgium)*

15.50-16.10

Harmonization of autoimmune serology in idiopathic inflammatory myopathies  
*Jan Damoiseaux (Maastricht, The Netherlands)*

16.10-16.30

ANA in autoimmune hepatitis: detection on HEp-2 cells versus rodent tissues  
*Werner Klotz, Manfred Herold (Innsbruck, Austria)*

16.30-16.50

Challenge of harmonization of antiphospholipid antibody detection  
*Pier Luigi Meroni (Milan, Italy)*

16.50-17.10

Two decades of autoantibody external proficiency testing at INSTAND e.V. in Germany - what can we expect, what have we learned?  
*Martin Blüthner, Marie Mayrhofer, Dietlind Lenz (Karlsruhe, Germany)*

17.10-17.30

Harmonization of autoantibody detection in the past decades: lessons learned from UK NEQAS external quality assessment  
*Teresa Carbone, Emirena Garrafa, Maria Infantino (Potenza, Italy)*

TUESDAY  
SEPTEMBER 12

**08.00-22.00**

**Registration**

**10.00-10.30**

**Welcome and Introduction**

Karsten Conrad (Dresden, Germany)

**10.30-12.00**

**Keynote and Memory Lectures**

Co-Chairs: Marvin Fritzler (Calgary, Canada)  
Yehuda Shoenfeld (Tel Aviv, Israel)

10.30-11.15

From prediction to prevention of autoimmune disease development  
*Yehuda Shoenfeld (Tel Aviv, Israel)*

11.15-11.30

Noel R. Rose (Baltimore, USA) - The father of modern  
autoimmunology  
*Yehuda Shoenfeld (Tel Aviv, Israel)*

11.30-11.45

Allan S. Wiik (Copenhagen, Denmark) - The father of harmonization  
*Johan Rönnelid (Uppsala, Sweden)*

11.45-12.00

Pierre Youinou (Brest, France) - A founder in the field of  
immunopathology of autoimmune diseases  
*Yves Renaudineau (Toulouse, France)*

12.00-13.30

LUNCH BREAK – POSTER AND EXHIBITION VIEWING

**Posters A1 – A19:** Guided poster presentation of selected posters of  
the Candidates for the Dresden Prize chaired by Dirk Reinhold  
(Magdeburg, Germany)

**13.30-15.00**

**ROLE OF AUTOANTIBODIES IN THE PREDICTION AND  
CLASSIFICATION OF AUTOIMMUNE DISEASES**

Co-Chairs: Thorsten Krieger (Hamburg, Germany)  
Maria Infantino (Florence, Italy)

13.30-14.00

The importance of autoantibodies for diagnosis, prognosis and  
classification of rheumatoid arthritis  
*Günter Steiner (Vienna, Austria)*

14.00-14.20

Differentiation of idiopathic inflammatory myopathies by increasing  
number of myositis specific and myositis associated autoantibodies  
*Fabricio Espinosa (Stockholm, Sweden)*

14.20-14.40

New developments in the classification of the Antiphospholipid  
Syndrome  
*Pier Luigi Meroni (Milan, Italy)*

- 14.40-15.00 Sarcoidosis: A comprehensive review of clinical cases in Brazil with focus on autoimmune features  
*Carlos A. von Mühlen (San Diego, USA)*
- 15.00-16.00 COFFEE BREAK
- 16.00-18.00** **AUTOANTIBODY PROFILING IN AUTOIMMUNE DISEASES USING PARTICLE-BASED MULTI-ANALYTE TECHNOLOGIES**  
(sponsored by Werfen)
- Co-Chairs: Marvin Fritzler (Calgary, Canada)  
Michael Mahler (San Diego, USA)
- 16.00-16.30 Multi-analyte testing in autoimmunity: From early days to modern technologies  
*Michael Mahler (San Diego, USA)*
- 16.30-17.00 Autoantibodies in idiopathic inflammatory myopathies  
*Marvin Fritzler (Calgary, Canada)*
- 17.00-17.20 Predicting progression from undifferentiated connective tissue disease to clinically overt disease using particle-based multi-analyte technology  
*Savino Sciascia (Torino, Italy)*
- 17.20-17.40 Anti-PAD antibodies in diagnosis and management of Rheumatoid Arthritis  
*Laura Martinez-Prat (Madrid, Spain)*
- 17.40-18.00 Novel autoantibodies in systemic sclerosis detected using multi-analyte testing  
*Marco de Pinto (Modena, Italy)*
- 18.00-22.00** **WELCOME RECEPTION with traditional and vegetarian Barbecue IN THE INDUSTRIAL EXHIBITION - POSTER AND EXHIBITION VIEWING**

WEDNESDAY  
SEPTEMBER 13

**08.30-10.30 RESULTS TO DECISION MAKING: INCORPORATING LIKELIHOOD RATIOS (LR) WITHIN MEDICAL PRACTICE**

(sponsored by Thermo Fisher Scientific)

Co-Chairs: Xavier Bossuyt (Leuven, Belgium)  
Veena Joy (Philadelphia, USA)

- 08.30-08.40 Introduction  
*Veena Joy (Philadelphia, USA)*
- 08.40-09.00 Current landscape of LR - Use of LR in diagnosis and prediction of clinical RA  
*Kevin D. Deane (Denver, USA)*
- 09.00-09.20 Practical application of LR within Rheumatoid Arthritis  
*Lieve Van Hoovels (Aalst, Belgium)*
- 09.20-09.40 LR in autoimmune diagnostics and beyond - Personal experience with LR in practice  
*Xavier Bossuyt (Leuven, Belgium)*
- 09.40-10.00 Industry perspective on LR  
*Nina Olschowka (Freiburg, Germany)*
- 10.00-10.25 Cross-fire discussion on LR  
*Moderator Veena Joy (Philadelphia, USA)*
- 10.25-10.30 Conclusion  
*Veena Joy (Philadelphia, USA)*

10.30-11.00 COFFEE BREAK - POSTER AND EXHIBITION VIEWING

**11.00-12.30 SEROLOGY OF RHEUMATOID ARTHRITIS – UPDATE AND NEW AUTOANTIBODIES**

Co-Chairs: Günter Steiner (Vienna, Austria)  
Ger J. M. Pruijn (Nijmegen, The Netherlands)

- 11.00-11.30 Autoantibodies in Rheumatoid Arthritis – Laboratory and Clinical Perspectives  
*Johan Rönnelid (Uppsala, Sweden)*
- 11.30-11.55 Pre-RA: Can early diagnosis lead to prevention?  
*Kevin D. Deane (Denver, USA)*
- 11.55-12.15 Novel Autoantibodies in “seronegative” RA  
*Daniela Sieghart (Vienna, Austria)*
- 12.15-12.30 Novel antibodies that predict failure to reach early and sustained remission or low disease activity after first-line therapy in rheumatoid arthritis  
*Sukayna F. Fadlallah, P. Vandormael, P. Ruytinx, A. Pues, E. Sleurs, J. Liesenborgs, J Joly; P. Verschueren, F. Vandenabeele, J. Fraussen, V. Somers (Hasselt & Leuven, Belgium)*

- 12.30-14.00 LUNCH BREAK – POSTER AND EXHIBITION VIEWING
- Posters B1 – B33:** Guided poster presentation of selected posters (systemic autoimmune diseases – clinical aspects & advances in routine diagnostics) chaired by Thorsten Krieger (Hamburg, Germany)
- 12.30-14.00 **EASI FORUM MEETING** (EASI members only)  
Location: Meeting room “Palaiszimmer”
- 14.00-15.20 **NOVEL THERAPIES OF AUTOIMMUNE DISEASES**
- Co-Chairs: Ger J. M. Pruijn (Nijmegen, The Netherlands)  
Manfred Herold (Innsbruck, Austria)
- 14.00-14.30 From hope to success – targets and targeted therapies in inflammatory rheumatic diseases  
*Nicolai Leuchten (Dresden, Germany)*
- 14.30-15.00 New hope? Novel therapies targeting B and plasma cells in systemic autoimmune diseases  
*Martin Aringer (Dresden, Germany)*
- 15.00-15.20 “Untargeting” autoantibodies using genome editing - A proof-of-concept study for a novel antigen-specific targeted therapy  
*Gerson Dierly Keppeke (São Paulo, Brazil)*
- 15.20-16.00 COFFEE BREAK
- 16.00-18.00 **SEROLOGY OF ANA ASSOCIATED RHEUMATIC DISEASES – UPDATE AND NEW AUTOANTIBODIES**
- Co-Chairs: Johan Rönnelid (Uppsala, Sweden)  
Carlos von Mühlen (San Diego, USA)
- 16.00-16.25 Autoantibodies as stratification tools for prediction and treatment decisions in ANA associated rheumatic diseases  
*May Choi (Calgary, Canada)*
- 16.25-16.45 Controversies of anti-dsDNA testing  
*Jan Damoiseaux, Joyce van Beers (Maastricht, The Netherlands)*
- 16.45-17.00 Urinary sCD163 performs better than anti-C1q and anti-dsDNA antibodies as biomarker in lupus nephritis for monitoring remission and impending flares  
*Yves Renaudineau, Dominique Chauveau, Stanislas Faguer, Antoine Huart, David Ribes, Gregory Pugno, Laurent Sailler, Thibaut Jamme, Emmanuel Treiner, Françoise Fortenfant, Chloé Bost, Caroline Carlé, Julie Bellière (Toulouse, France)*
- 17.00-17.15 Rare (new) autoantigens in systemic sclerosis and how to detect them  
*Jean-Baptiste Vulsteke, Xavier Bossuyt (Leuven, Belgium)*
- 17.15-17.30 The never-ending story of antibodies in systemic sclerosis

*Alessandra Melegari, Elena De Santis, Tommaso Pirotti, Marco de Pinto, Maria Teresa Mascia, Amelia Spinella, Tommaso Trenti, Dilia Giuggioli (Modena, Italy)*

17.30-17.45 Added value of Systemic Sclerosis and anti-synthetase antibody testing on ILD classification in patients with distinct radiological HRCT pattern

*Lieve Van Hoovels, Bert Van der Cruyssen, Bo Massa, Stefanie Van Den Breemt, Lieven Van Hoe, Xavier Bossuyt, Wim Wuyts, Valerie Adam (Aalst & Leuven, Belgium)*

17.45-18.00 Anti-KIF20B Autoantibodies are Associated with Cranial Neuropathy in Systemic Lupus Erythematosus

*Eugene Krustev, John G. Hanly, Ricky Chin, Katherine A. Buhler, Marvin J. Fritzler, Ann E. Clar, May Y. Choj, on behalf of the Systemic Lupus International Collaborating Clinics (SLICC) group (Calgary & Halifax, Canada)*

THURSDAY  
SEPTEMBER 14

**08.30-10.30**

**AUTOANTIBODY ASSOCIATED NEUROLOGICAL DISEASES**

(sponsored by Euroimmun Medizinische Labordiagnostika AG, Lübeck, Germany)

Co-Chairs: Josep Dalmau (Barcelona, Spain)  
Klaus Peter Wandinger (Lübeck, Germany)

08.30-09.00 The antibody-mediated encephalitis - From discovery to new clinical insights and mechanisms

*Josep Dalmau (Barcelona, Spain)*

09.00-09.30 The clinical impact of antibody testing in Neurology

*Klaus Peter Wandinger (Lübeck, Germany)*

09.30-09.50 Paraneoplasias: Antibody mediated diseases of the peripheral nervous system

*Frank Leypoldt (Kiel, Germany)*

09.50-10.10 Autoimmune encephalitis: connecting clinical clues and immunological fingerprints

*Maarten Titulaer (Rotterdam, The Netherlands)*

10.10-10.20 Discovery of autoantibodies in autoimmune neurological syndromes

*Madeleine Scharf (Lübeck, Germany)*

10.20-10.30 Identification of neural autoantigens by combining indirect immunofluorescence of tissue sections and phage immunoprecipitation sequencing (PhIP-seq)

*Stefan Schöbel, Madeleine Scharf, Ramona Miske, Christiane Radzinski, Kathrin Borowski, Winfried Stöcker (Lübeck, Germany)*

10.30-11.00 COFFEE BREAK - POSTER AND EXHIBITION VIEWING



11.00-12.30

## EASI SYMPOSIUM

### AUTOANTIBODIES IN AUTOIMMUNE HEPATITIS

Co-Chairs: Jan Damoiseaux (Maastricht, The Netherlands)  
Dimitrios Bogdanos (Larissa, Greece)

11.00-11.25

Autoimmune Hepatitis Societies and awareness of difficulties in autoantibody detection  
*Dimitrios Bogdanos (Larissa, Greece)*

11.25-11.50

Non-invasive diagnosis and follow-up of autoimmune hepatitis events  
*Sara Lemoine (Paris, France)*

11.50-12.10

Implications of discrepancies in autoantibody detection for AIH between guidelines and routine  
*Georgios N. Dalekos (Larissa, Greece)*

12.10-12.30

Autoantibodies generated after liver transplantation  
*Nedim Hadzic (London, UK)*

12.30-14.00

### LUNCH BREAK – POSTER AND EXHIBITION VIEWING

**Posters C1-C32:** Guided poster presentation of selected posters (organ specific autoimmune diseases, SARS-CoV-2 infection) chaired by Ulrich Sack (Leipzig, Germany)

14.00-15.30

### SEROLOGY OF ORGAN SPECIFIC AUTOIMMUNITY – UPDATE AND NEW AUTOANTIBODIES

Co-Chairs: Christian P. Moritz (Saint-Etienne, France)  
Lieve Van Hoovels (Aalst, Belgium)

14.00-14.20

Autoantibodies in peripheral neuropathies – What are the news?  
*Christian P. Moritz (Saint-Etienne, France)*

14.20-14.40

Novel autoantigen peptide epitopes as theranostic targets in incurable autoimmune blistering diseases  
*Simon Lytton (Munich, Germany)*

14.40-14.55

Autoimmune encephalitis: the specific cell-based assays are not enough and it is essential to analyze neuronal tissue reactivity!  
*Martina Fabris, Alberto Vogrig, Veronique Rogemond, Francesco Ellero, Mariarosaria Valente, Jerome Honnorat, Francesco Curcio (Udine, Italy & Lyon, France)*

14.55-15.10

Anti-p56 in patients with Idiopathic Pulmonary Fibrosis targets Annexin A11

*Fionnuala McMorro, Janire Perurena-Prieto, Caroline V. Cotton, Zoe E. Betteridge, Janine A. Lamb, Hui Lu, Robert P. New, Lisa G. Spencer, Sarah L. Tansley, Neil J. McHugh and the UK-BILD Collaboration (Bath, UK)*

15.10-15.30 Results of a novel multiparametric test for gluten related diseases in a pediatric cohort  
*Torsten Matthias, Patricia Wusterhausen, Simon Lytton (Wendelsheim & Munich, Germany)*

15.30-16.00 COFFEE BREAK

**16.00-18.00 INFECTION, VACCINATION AND THERAPY ASSOCIATED AUTOIMMUNITY**

Co-Chairs: Yehuda Shoenfeld (Tel Aviv, Israel)  
Ulrich Sack (Leipzig, Germany)

16.00-16.30 COVID-19, post-COVID-19, COVID -19 vaccine and autoimmunity  
*Yehuda Shoenfeld (Tel Aviv, Israel)*

16.30-16.50 Rheumatic symptoms after Covid infection or vaccination  
*Manfred Herold (Innsbruck, Austria)*

16.50-17.10 Functional implications of promiscuous autoantibodies in COVID-19  
*Mikhail Lebedin, Clara Vázquez Garcia, Lisa Spatt, Christoph Ratswohl, Charlotte Thibeault, Lennard Ostendorf, Tobias Alexander, Friedemann Paul, Leif Eric Sander, Florian Kurth, Kathrin de la Rosa (Berlin, Germany)*

17.10-17.25 Bullous Pemphigoid induced by anti-PD1 medication  
*Jean Milhès, Caroline Carlé, Yves Renaudineau, Chloé Bost, Françoise Fortenfant (Toulouse, France)*

17.25-17.45 Detection and Clinical Relevance of Non-HLA Autoantibodies in Kidney Transplantation  
*Henny Otten (Utrecht, The Netherlands)*

17.45-18.00 Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)  
*A. Daban, C. Gonnin, L. Phan, A. Saldmann, C. Granier, A. Lillo-Lelouet, C. Le Beller, J. Pouchot, L. Weiss, E. Tartour, E. Fabre, J. Medioni, S. Oudard, Y.A. Vano, Marie-Agnes Dragon-Durey, A. Simonaggio (Paris, France)*

18.15 **Departure by shuttle bus from the congress venue to the Social Dinner venue**

19.00-22.00 **Social Dinner**

FRIDAY,  
SEPTEMBER 15

**08.30-10.30**

**NEW INSIGHTS IN THE DIAGNOSIS AND PATHOPHYSIOLOGY OF  
AUTOIMMUNE CHOLANGITIS AND INTESTINAL DISORDER**

(sponsored by Medipan GmbH, Dahlewitz, Germany)

Co-Chairs: Dimitrios Bogdanos (Larissa, Greece)  
Dirk Roggenbuck (Dahlewitz, Germany)

08.30-09.00

Primary biliary cholangitis: the disease of 100 autoantibodies  
*Dimitrios Bogdanos (Larissa, Greece)*

09.00-09.15

PR3-ANCA detected by third-generation ELISA predicts severe disease  
and poor survival in primary sclerosing cholangitis  
*Dirk Roggenbuck (Dahlewitz, Germany)*

09.15-09.30

Antimicrobial autoantigenic glycoprotein 2 in bile and gallstones  
secreted by peribiliary glands - a novel autoimmune target in PSC  
*Steffi Lopens (Dahlewitz, Germany)*

09.30-09.45

Molecular mimicry in primary biliary cholangitis accounts for disease-  
specific anti-nuclear antibodies  
*Dimitrios Bogdanos (Larissa, Greece)*

09.45-10.00

Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a novel  
diagnostic biomarker in cholangiocarcinoma without concomitant  
primary sclerosing cholangitis  
*Chang-sheng Xia (Beijing, China)*

10.00-10.15

Human antimicrobial glycoprotein-2 expressed in Brunner glands – a  
putative autoimmune target and link between Crohn's and celiac  
disease  
*Martin Laass (Dresden, Germany)*

10.15-10.30

Antiphospholipid antibodies are enriched after post acute COVID-19  
but do not modulate the thrombotic risk  
*Dirk Roggenbuck (Dahlewitz, Germany)*

10.30-11.00

COFFEE BREAK - POSTER AND EXHIBITION VIEWING

**11.00-12.45**

**CHALLENGES AND ADVANCES IN AUTOANTIBODY DETECTION**

Co-Chairs: Xavier Bossuyt (Leuven, Belgium)  
Pier Luigi Meroni (Milan, Italy)

11.00-11.25

Identification of autoantibodies recognizing conformational epitopes  
by immunoprecipitation – mass spectrometry  
*Xavier Bossuyt, Jean-Baptiste Vulsteke (Leuven, Belgium)*

11.25-11.45

Autoantigenomics: Exploring patterns in the repertoires of  
autoantibody-targeted proteins  
*Christian P. Moritz (Saint-Etienne, France)*

- 11.45-12.00 Comparison of prospective anti-double stranded DNA (dsDNA) assays relative to antinuclear antibodies and Crithidia luciliae indirect fluorescent test  
*Patrick Vanderboom, Karin Braun, Michelle Campbell, Melissa Snyder, Anne Tebo (Rochester, USA)*
- 12.00-12.15 A comparison of methods for the detection of anti-cN1A autoantibodies in patient sera  
*Ger J. M. Pruijn (Nijmegen, The Netherlands)*
- 12.15-12.30 Pursuing appropriateness in antiphospholipid antibodies testing: feasibility study with a reflex test approach for anti-beta-2-glycoprotein I domain 1  
*Maria Infantino (Florence), Savino Sciascia (Torino, Italy)*
- 12.30-12.45 Ex vivo demonstration of Lupus Anticoagulant Phenomenon and Thrombin Generation Activity induced by Anti-Prothrombin Antibodies  
*Alice Barinotti, Silvia Foddai, Cristina Garcia, Mar Petit-Pedrol, Ingrid González, Laura Martinez, Eduard Martinez, Gisela Riera, Javier Hervás, Patricia Rogniat, Rocio Doval, Barbara Montaruli, Michael Mahler, Savino Sciascia, David Lucia, Irene Cecchi and Massimo Radin (Turin, Italy; Barcelona, Spain; San Diego, USA)*
- 12.45-13.45 LUNCH BREAK – POSTER AND EXHIBITION VIEWING
- 13.45-14.50 UPDATE ON ANTI-DFS70 AUTOANTIBODIES**  
Co-Chairs: Carlos Casiano (Loma Linda, USA)  
Luis E.C. Andrade (São Paulo, Brazil)
- 13.45-14.10 Recent advances on the biology of the DFS70/LEDGFp75 autoantigen: clues for understanding the significance of the anti-DFS autoantibody response.  
*Carlos Casiano (Loma Linda, USA)*
- 14.10-14.35 Anti-DFS70 autoantibodies: is there any evidence in support of underlying molecular mimicry?  
*Dimitrios Bogdanos (Larissa, Greece)*
- 14.35-14.50 Over-expression of LEDGF/p75 in HEp-2 cells enhances autoimmune IgG response in patients with benign prostatic hyperplasia - a novel diagnostic approach with therapeutic consequence?  
*Victoria Liedtke (Senftenberg, Germany)*
- 14.50-15.15 Dresden Prize Award Ceremony & Conclusion**
- 15.15-16.00 FAREWELL COFFEE BREAK

TUESDAY  
SEPTEMBER 12  
(12.30) until  
FRIDAY,  
SEPTEMBER 15  
(13.45)

## POSTER EXHIBITION

### A CANDIDATES FOR THE DRESDEN PRIZE

**A1** Identification and characterization of novel functional autoantibodies associated with systemic sclerosis. *Jacqueline Wax, B. Kaspe, G. Riemekasten, F. Petersen, X. Yu (Borstel, Germany)*

**A2** Comparison of Aptiva and routine methods for the detection of antibodies associated with connective tissue disease in an Australian laboratory. *Lucinda Wallman, Kartik Naidu, Chelsea Bentow, Mary Ann Aure, Michael Mahler (San Diego, USA)*

**A3** Ex vivo demonstration of Lupus anticoagulant phenomenon and thrombin generation activity induced by anti-prothrombin antibodies. *Alice Barinotti, Silvia Foddai, Cristina Garcia, Mar Petit-Pedrol, Ingrid González, Laura Martinez, Eduard Martinez, Gisela Riera, Javier Hervás, Patricia Rogniat, Rocio Doval, Barbara Montaruli, Michael Mahler, Savino Sciascia, David Lucia, Irene Cecchi and Massimo Radin (Turin, Italy)*

**A4** Anti-pyruvate dehydrogenase autoantibodies may be of functional relevance in patients with suspected autoimmune encephalitis. *Juliane L. Berns, Annika Breuer, Tobias Baumgartner, Chiara A. Hummel, Afaf Milad Said, Susanne Schoch, Wolfram Kunz, Rainer Surges, Albert Becker, Julika Pitsch (Bonn, Germany)*

**A5** Discriminating signal from noise: the biological variation of circulating calprotectin. *Marth Briers, Bert Vander Cruyssen, Bo Massa, Stefanie Van Den Bremt, Laura Hofman, Ann Belmans, Bernhard Hoermann, Xavier Bossuyt, Lieve Van Hoovels (Aalst, Belgium)*

**A6** Bullous Pemphigoid (BP) induced by Anti-PD1 medication. *Jean Milhès, Caroline Carlé, Yves Renaudineau, Chloé Bost, Françoise Fortenfant (Toulouse, France)*

**A7** Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic Lupus erythematosus. *Eugene Krustev, John G. Hanly, Ricky Chin, Katherine A. Buhler, Marvin J. Fritzier, Ann E. Clar, May Y. Choi, on behalf of the Systemic Lupus International Collaborating Clinics (SLICC) group (Calgary, Canada)*

**A8** Clinical and laboratory re-evaluation of anti-GFAP antibody positive patients. *Justina Dargvainiene, K.K. Falk, L. Abrante, F. Leypoldt, R. Markewitz, R. Junker, D. Kixmüller, K.H. Stürner, J. Emad, K.-P. Wandinger (Kiel, Germany)*

**A9** Novel antibodies that predict failure to reach early and sustained remission or low disease activity after first-line therapy in rheumatoid arthritis. *Sukayna F. Fadlallah, P. Vandormael, P. Ruytinx, A. Pues, E. Sleurs, J. Liesenborgs, J Joly; P. Verschueren, F. Vandenabeele, J. Fraussen, V. Somers (Hasselt, Belgium)*

**A10** Functional implications of promiscuous autoantibodies in COVID-19. *Mikhail Lebedin, Clara Vázquez García, Lisa Spatt, Christoph Ratswohl, Charlotte Thibeault, Lennard Ostendorf, Tobias Alexander, Freidemann Paul, Leif Eric Sander, Florian Kurth, Kathrin de la Rosa (Berlin, Germany)*

**A11** Over-expression of LEDGF/p75 / DFS70 in HEP-2 cells enhances autoimmune IgG response in patients with benign prostatic hyperplasia - a novel diagnostic approach with therapeutic consequence? *Victoria Liedtke, Laura Rose, Rico Hiemann, Abdullah Nasser, Stefan Rödiger, Alena Bonaventura, Laura Winkler, Mandy Sowa, Michael Stöckle, Peter Schierack, Kerstin Junker, Dirk Roggenbuck (Senftenberg, Germany)*

**A12** Anti-p56 in patients with idiopathic pulmonary fibrosis targets annexin A11. *Fionnuala McMorrough, Janire Perurena, Caroline V Cotton, Zoe E Betteridge, Janine A Lamb, Hui Lu, Robert P New, Lisa G Spencer, Sarah L Tansley, Neil J McHugh and the UK-BILD Collaboration (Bath, UK)*

**A13** Silencing the DFS70/LEDGFp75 autoantigen reveals potential roles in lymphocyte function and immune evasion. *Pedro T. Ochoa, Evelyn S. Sanchez-Hernandez, Issac Kremsky, Charles Wang, Carlos A. Casiano (Loma Linda, USA)*

**A14** In early rheumatoid arthritis, anti-citrullinated peptide antibodies associate with low number of affected joints, and rheumatoid factor with systemic inflammation. *Eleftheria Pertsinidou, Saedis Saevarsdottir, Vivek Anand Manivel, Lars Klareskog, Lars Alfredsson, Linda Mathsson Alm, Monika Hansson, Martin Cornillet, Guy Serre, Rikard Holmdahl, Karl Skriner, Per-Johan Jakobsson, Helga Westerlind, Johan Askling, Johan Rönnelid (Uppsala, Sweden)*

**A15** Generation and evaluation of conformation-specific antibodies to prothrombin from antiphospholipid syndrome (APS) patients. *Mar Petit-Pedrol, Eduard Martinez-Llpart, Alice Barinotti, Silvia Foddaj, Irene Cecchi, Massimo Radin, Ingrid González, Gisela Riera, Cristina Garcia, Javier Hervás, Patricia Rogniat, Rocio Doval, Michael Mahler, Savino Sciascia, David Lucia (Barcelona, Spain)*

**A16** Identification of novel antigenic targets using antibody profiling in spinal cord injury patients. *Astrid Pues, C.C.M. Van Laake-Geelen, S. Bamps, E.M.J. Cornips, J. Deckers, D. Peuskens, B. Depreitere, M. Ruitenbergh, P. Vandormael, J. Fraussen, V. Somers (Hasselt, Belgium)*

**A17** Paraneoplastic ataxia-ophthalmoplegia syndrome associated with anti-Ri antibodies: a case report. *Cecilia Simonini, Elena de Santis, Ilaria Martinelli, Nicola Fini, Cecilia Napodano, Tommaso Trenti, Alessandra Melegari (Modena, Italy)*

**A18** Advancing autoimmune encephalopathy diagnosis: Leveraging cell-free protein synthesis for enhanced detection of autoantibodies. *Jessica Ullrich, Harald Prüss, Stefan Kubick, Anne Zemella (Potsdam, Germany)*

**A19** Identification of new autoantigens in HEP-2 IIFA-positive usual interstitial pneumonia without known autoantibody. *Jean-Baptiste Vulsteke, Nico Decrem, Jonas Yserbyt, Adriana Dubbeldam, Ellen De Langhe, Wim A Wuyts, Xavier Bossuyt (Leuven, Belgium)*

## **B SYSTEMIC AUTOIMMUNE DISEASES**

**B1** Prevention and early diagnosis of rheumatoid arthritis (RA) – The DigiPrevent project. *Lisa Christiansson, Isabel Gehring, Marta Lason, Rachel Knevel, Johannes Knitza, Lars Klareskog, Per-Johan Jakobsson (Uppsala, Sweden)*

**B2** Leveraging the combination of classification criteria biomarkers and demographic information to improve Rheumatoid Arthritis diagnosis. *Franco Franceschini, Emirena M. Garrafa, Brooke Holloway, Mary Ann Aure, Carlos Melus, Chelsea Bentow, Laura Martinez-Prat, Silvia Piantoni, Alessia Caproli, Michael Mahler (Brescia, Italy)*

**B3** NORA and ScandRA – Personalised medicine in RA by combining genomics, biomarkers, clinical and patient-data from the Scandinavian countries. *Jessica Rojas-Restrepo, Isabel Gehring, Bente Glintborg, Hilde Berner Hammer, Niels Steen Krogh, Johan Rönnelid, Johan Askling (Freiburg, Germany)*

**B4** Prevalence and role of serum biomarkers in rheumatoid arthritis associated interstitial lung disease. *Albert Pérez-Isidro, Cornellà de Llobregat, Juan Camilo Sarmiento-Monroy, Raul Castellanos-Moreira, Noemí de Moner, Judit Becerra, Anna Colmenero, Manuel Morales-Ruiz, Raimon Sanmartí, José Alfredo Gomez-Puerta, Mercè Tena, Maresa Grundhuber, Estíbaliz Ruiz-Ortiz Odette Viñas (Barcelona, Spain)*

**B5** Clinical performance and method comparison of Aptiva CCP3 for the detection of anti-citrullinated protein antibodies using a particle-based multi-analyte technology. *Andrew Ishii, Chelsea Bentow, Sara Rew, Matthew Hashimoto, Michael Mahler (San Diego, USA)*

**B6** An agglutination assay for ACPA detection in rheumatoid arthritis patients. *Ilmar Kruis, Annemarie van der Heijden, Martin Salden, Ger Pruijn (Nijmegen, The Netherlands)*

**B7** Circulating calprotectin in rheumatoid arthritis: unravelling the impact of (pre-)analytical confounders on meta-analysis results. *Bo Massa, Marnix Mylemans, Bert Vander Cruyssen, Maria Infantino, Xavier Bossuyt, Lieve Van Hoovels (Aalst, Belgium)*

**B8** Evaluation of circulating levels of soluble urokinase plasminogen activator receptor (suPAR) in a cohort of patients with chronic arthritis. *Emirena M. Garrafa, Paola Bizioli, Silvia Piantoni, Marika Vezzoli, Duilio Brugnoli, Alessia Caproli, Ilaria Cavazzana, Franco Franceschini (Brescia, Italy)*

**B9** Assessment of Systemic Sclerosis markers utilizing a particle-based multi-analyte technology in an Italian cohort for the very early diagnosis of systemic sclerosis (vedoss). *Marco de Pinto, Maria Teresa Mascia, Dilia Giuggioli, Amelia Spinella, Elena De Santis, Michael Mahler, Chelsea Bentow, Sara Rew, Andy Ishii, Mary Ann Aure, Alessandra Melegari (Modena, Italy)*

**B10** IgA Autoantibodies in Systemic Sclerosis Patients. *Albert Pérez-Isidro, Maresa Grundhuber, Gema M Lledó-Ibáñez, Noemí de Moner, Maria Torradeflot, María José Martínez, Gerard Espinosa, Mercè Tena, Odette Viñas, Estíbaliz Ruiz-Ortiz (Barcelona, Spain)*

**B11** Does anti-Ro52 antibodies have an impact in diagnosis of systemic autoimmune diseases? *Nese Kaklikkaya, Neval Yurttutan Uyar, Esvet Mutlu, Nilgun Kasifoglu, Rukiye Berkem, Tutku Taskinoglu, Aylin Somun Ocakli, Pinar Tufanoglu, Oyku Simsek, Gozde Ongut, Esra Ozkaya, Mustafa Ekici, Metin Sancaktar, Busra Sultan Cesur, Ilyas Ercan Okatan, Omer Karadag, Veli Yazisiz, Timucin Kasifoglu, Burcin Sener (Trabzon, Turkey)*

**B12** Performance of a novel, fully automated planar microarray immunoassay for the detection of autoantibodies against Centromere Protein B and correlations with autoimmune disease diagnosis. *Makoto Miyara, Christel Daubrosse, Valerie Mercier, Rocio Pasion Galvan, Daphne Bijlsma, Ewa Lukasik, Valeria Botti, Gerber Gomez, Emmanuel Moreau, Christine C. Ginocchio, Michael Hausmann, Pascale Ghillani-Dalbin (Eysins, Switzerland)*

**B13** Anti-Mi2 assays - Are they interchangeable? *Yesenia Jiménez de las Pozas, M Carmen Vegas Sánchez, Natalia Casado Navarro, Rosales Dávila, Alexandra Mariam, María José Martínez Becerra, (Madrid, Spain)*

**B14** Anti-Th/To: Clues for facing puzzling results. *Ángel López Brull, Maria del Carmen Vegas Sánchez, Natalia Casado Navarro, Marian Dávila Rosales, María José Martínez Becerra (Madrid, Spain)*

**B15** Anti-Mi2 and anti-CENPB, An odd finding? *Yesenia Jiménez De Las Pozas, María Del Carmen Vegas Sánchez, Natalia Casado Navarro, Mariam Alexandra Dávila Rosales, María José Martínez Becerra (Madrid, Spain)*



**B16** Adjustment of the band intensity value for myositis specific and associated autoantibodies using line-blot techniques. *Albert Pérez-Isidro, Mario Framil-Seoane, María Torradeflot, Noemí de Moner, Judit Becerra, Odette Viñas, María Ortiz-Fernández, Sergio Prieto-González, Estíbaliz Ruiz-Ortiz (Barcelona, Spain)*

**B17** Prevalence of Autoantibodies Directed Against Secondary Necrotic Cells in SLE Patients. *Ekaterina Vogt, Maresa Grundhuber, Sascha Swiniarski, Luis Muñoz (Freiburg, Germany)*

**B18** Isolated ribosomal P antibodies, are they useful clinically? *María Begoña Just Balerdi, Natalia Casado Navarro, Marian Alexandra Dávila Rosales, Elena Sancho Cadenas, María José Martínez Becerra, María Del Carmen Vegas Sánchez, Karina Guzmán López (Madrid, Spain)*

**B19** Efficacy of intravenous immunoglobulin therapy in a haematological form of systemic lupus erythematosus: a case report. *Svetla Blazheva, Borislava Zhelezarova, Ralitsa Pencheva, Jana Schauer, Tzvetan Lukanov, Emiliana Konova (Pleven, Bulgaria)*

**B20** Impact of imlifidase treatment on immunoglobulins in an HLA-hypersensitized SLE patient with anti-SSA/SSB antibodies after kidney transplantation. *Jean Milhès, Olivier Marion, Benedicte Puissant, Charlène Bouthemy, Arnaud Del Bello, Nassim Kamar, Caroline Carlé, Yves Renaudineau, Nicolas Congy-Jolivet (Toulouse, France)*

**B21** Isolation and characterization of anti-Prothrombin antibodies from Antiphospholipid syndrome (APS) patients: a tool to enhance patient stratification studies. *Cristina Garcia, Mar Petit-Pedrol, Ingrid González, Laura Martinez-Prat, Silvia Foddai, Alice Barinotti, Irene Cecchi, Massimo Radin, Eduard Martinez, Gisela Riera, Javier Hervás, Patricia Rogniat, Rocio Doval, Michael Mahler, Savino Sciascia, David Lucia (Barcelona, Spain)*

**B22** The presence of antibodies against DFS70 antigen are not correlated with antibodies against infectious antigens. *Eleni Patrikiou, Christos Liaskos, Niki Ntavari, Efterpi Zafiriou, Theodora Simopoulou, Thomas Scheper, Wolfgang Meyer, Aggeliki Roussaki-Schulze, Dimitrios P. Bogdanos (Larissa, Greece)*

**B23** Current application and interest of likelihood ratio reporting in autoimmune serology: results of a Belgian and EASI forum survey. *Lieve Van Hoovels, Sylvia Broeders, Jan Damoiseaux, Wim Coucke, Carolien Bonroy, Sylvie Goletti, Laurence Lutteri, Sofie Schouwers, Martine Vercammen, Xavier Bossuyt on behalf of the Belgian expert committee on non-infectious serology of Sciensano and the Belgian EASI working group (Aalst, Belgium)*

**B24** Comparison of a novel multi-analyte assay for the detection of autoantibodies in the diagnosis of connective tissue diseases with routine laboratory methods. *Yvonne Baus, Ivana Buettnerova, Jose Bernardino Gonzalez, Nadja Unterwalder, Johanna Bialas, Markus Hermanowski, Kevin Brea-Sellheim, Carlos Melus, Michael Mahler (München, Germany)*

**B25** Harmonization of ANA testing challenge: quantification strategy to accurately predict end-point titers avoiding serial dilution (7<sup>th</sup> ICAP workshop contribution). *Teresa Carbone, Vito Pafundi, Vito Ciardo, Maria Infantino, Salvatore D'Angelo (Potenza, Italy)*

**B26** Antinuclear Antibody-HEp-2 IIF Competency Assessment Programme of Society for Clinical Microbiologists of Türkiye: Analysis of Five-Year Results (7<sup>th</sup> ICAP workshop contribution). *Nilgun Kasifoglu, Neval Yurttutan Uyar, Ekrem Yasar, Nese Kaklikkaya, Tutku Taskinoglu, Burcin Sener (Istanbul, Turkey)*

**B27** Harmonization of autoantibody detection in the past decades: lessons learned from UK NEQAS external quality assessment (7<sup>th</sup> ICAP workshop contribution). *Teresa Carbone, Emirena Garrafa, Maria Infantino (Florence, Italy)*

**B28** Routinely use of BioCLIA®6500 (HOB Biotech/Eurobio Scientific), a novel chemiluminescent immunoanalyzer in autoimmune disease diagnostics. *N. Drouaz, E. Morain, L. Dufat, M. Miyara, Z. Amoura, Pascale Ghillani (Paris, France)*



**B29** Preliminary comparison between ELISA test routinely used and fully automated ELISA monostest system in solid-phase for the therapeutic drug monitoring. *Cecilia Napodano, Elena De Santis, Cecilia Simonini, Barbara Venturelli, Federica Laterza, Tommaso Pirotti, Tommaso Trenti, Alessandra Melegari (Modena, Italy)*

**B30** Likelihood ratios of anti-MPO and anti-PR3 antibodies for ANCA-associated vasculitis at diagnosis. *Manca Ogrič, Tinka Švec, Katjuša Mrak Poljšak, Polona Žigon, Alojzija Hočever, Saša Čučnik (Ljubljana, Slovenia)*

**B31** Identification of thresholds for moderate and high positive anticardiolipin and anti- $\beta$ 2-glycoprotein I levels detected by chemiluminescent assays. *Manca Ogrič, Polona Žigon, Nika Boštic, Tinka Švec, Katjuša Mrak Poljšak, Saša Čučnik (Ljubljana, Slovenia)*

**B32** Platform comparison and assessment of a 48-plex cytokine panel using a high throughput particle-based multi-analyte technology. *Mark Fritzier, Michael Mahler, Gary L Norman, Chelsea Bentow, Emily Claire Marusin, Sara Rew, Mary Ann Aure, Marvin Fritzier (San Diego, USA)*

**B33** Verification of Siemens latex anti-TNF-alpha nephelometric assay on ATELLICA NEPH630 nephelometer. *Andrea Tešija Kuna, Iva Otmačić, Marijana Miler, Sanja Brajković, Anita Horvat, Nora Nikolac Gabaj (Zagreb, Croatia)*

## C ORGAN SPECIFIC AUTOIMMUNE DISEASES AND SARS-CoV-2 INFECTION

**C1** Clonally expanded CSF plasma cells produce highly specific autoantibodies in patients with LGI1/CASPR2 autoimmune encephalitis. *Ligia Abrante, Daniela Esser, J. Dargvainiene, G. Meyer zu Hörste, M. Titulaer, N. Melzer, K.-P. Wandinger, F. Leypoldt (Kiel, Germany)*

**C2** GanglioCombi, a unique standardized multiparametric ELISA for the specific detection of anti-neural antibodies compliant with new regulatory IVDR standards. *Valeria Eckhardt, Christina Bauer, Renato Cotti, Marie-Eve Ueberschlag, Hüseyin Ilgü, Johannes Schneider, Stefan Neu, Sabine Kräuchi, Benjamin Ricken, Thomas Schuster, Christian-Benedikt Gerhold (Schönenbuch, Switzerland)*

**C3** Detection of anti-AMPA receptor autoantibodies using a new substrate for recombinant cell-based testing. *Esther Aguilar, Raquel Ruiz-García, Laura Naranjo, Alessandro Dario Confettura, Dominik Jäger, Swantje Mindorf, Sandra Saschenbrecker, Lidia Sabater, Josep Dalmau (Lübeck, Germany)*

**C4** Evaluation of EUROIMMUN anti-LGI1 cell-based assays: novel prototype versus commercial substrate. *Esther Aguilar, Raquel Ruiz-García, Laura Naranjo, Alessandro Dario Confettura, Dominik Jäger, Swantje Mindorf, Sandra Saschenbrecker, Lidia Sabater, Josep Dalmau (Lübeck, Germany)*

**C5** Performance assessment of the new EUROLINE Neurologic Syndrome 15 Ag (IgG) for the determination of autoantibodies associated with neurological disorders. *Anthonina Ott, Ramona Miske, Madeleine Scharf, Dominik Jäger, Anette Schulz, Thomas Scheper, Wolfgang Meyer, Lars Komorowski (Lübeck, Germany)*

**C6** Evaluation of the performance of the EUROIMMUN anti-GABA<sub>A</sub> Receptor IFA in patients with suspected autoimmune anti-GABA<sub>A</sub>R encephalitis. *Rose Kohlie, Eszter Barabás, Luise Zech, Erik Lattwein, Alessandro D. Confettura, Dominik Jäger, Anette Schulz, Zsuzsanna Beleznay (Lübeck, Germany)*

**C7** Simultaneous detection of multiple Purkinje cell antigens using the EUROLINE Purkinje Cell Profile (IgG). *Antonina Ott, Ramona Miske, Madeleine Scharf, Alessandro D. Confettura, Dominik Jäger, Anette Schulz, Thomas Scheper, Wolfgang Meyer, Lars Komorowski (Lübeck, Germany)*

**C8** Detection of autoantibodies against the acetylcholine receptor, evaluation of commercially available methodologies: fixed Cell-Based Assay, Radioimmunoprecipitation Assay and Enzyme-Linked Immunosorbent Assay. *Larissa Diogenes, Alessandra Dellavance, Danielle Cristiane Baldo, Sarah Cristina Gozzi e Silva, Kethellen Gomes, Monica Simon Prado, Luis Eduardo C. Andrade, Gerson Dierley Keppeke (Sao Paulo, Brazil)*

**C9** Detection of KLHL11 autoantibodies using a new cell-based indirect immunofluorescence assay. *Swantje Mindorf, Dominik Jäger, Lidia Sabater, Julika Pitsch, Tobias Baumgartner, Albert J. Becker, Adrian Budhram, Jérôme Honnorat, Sandra Saschenbrecker, Josep Dalmau, Lars Komorowski (Lübeck, Germany)*

**C10** Identification of DAGLA as an autoantibody target in cerebellar ataxia. *Ramona Miske, Madeleine Scharf, Kathrin Borowski, Ina Specht, Merle Corty, Monika-Johanna Loritz, Frederik Rombach, Guy Laureys, Nadine Rochow, Christiane Radzimski, Dominica Ratuszny, Thomas Skripuletz, Mike Wattjes, Stefanie Hahn, Yvonne Denno, Khadija Guerti, Matthijs Oyaert, Farid Benkhadra, Corinna Bien, Christian Probst, Bianca Teegen, Lars Komorowski, Kurt-Wolfram Sühs (Lübeck, Germany)*

**C11** Septin-3 as a novel autoimmune target antigen in patients with paraneoplastic cerebellar ataxia. *Madeleine Scharf, Ramona Miske, Kathrin Borowski, Nicole Rieckhoff, Bianca Teegen, Yvonne Denno, Christian Probst, Kersten Guthke, Ieva Didrihsone, Brigitte Wildemann, Klemens Ruprecht, Lars Komorowski, Sven Jarius (Lübeck, Germany)*

**C12** Immune checkpoint inhibitor-related myotoxicity: musculoskeletal and/or neuromuscular junction disorder? *Lotta Plomp, Hortense Chassepot, Dimitri Psimaras, Thierry Maisonobe, Eric Mensi, Sarah Leonard-Louis, Isabelle Plu, Mehdi Touat, Celine Anquetil, Nadege Wesner, Nicolas Champtiaux, Aude Rigolet, Sophie Demeret, Nicolas Weiss, Marie-Alexandra Alyanakian, Marie-Agnès Dragon-Durey, Lucienne Chatenoud, Baptiste Abbar, Antoine Rozes, Marie-Claire Bretagne, Bruno Pinna, Thomas Similowski, Capucine Morelot, Martin Dres, Stephane Ederhy, Olivier Benveniste, Joe-Elie Salem, Yves Allenbach (Paris, France)*

**C13** Neuronal autoantibodies: Evaluation of a seven years experience as a reference clinical laboratory. *Maria José Sousa, Margarida Albuquerque, Catarina Castaldo, Rita Ribeiro, José Germano de Sousa, Germano de Sousa (Lisboa, Portugal)*

**C14** The enigma of sclera-specific autoimmunity in scleritis. *Daphne P.C. Vergouwen, Adriaan A. van Beek, Joeri de Hoog, Joke H. de Boer, Leonoor I. Los, Marlies Gijs, Roel J. Erckens, R.M. Verdijk, Dave L. Roelen, Aniki Rothova, Johan Rönnelid, Josianne C. Ten Berg, Marco W.J. Schreurs (Rotterdam, The Netherlands)*

**C15** Utility of PR3-ANCA in patients with inflammatory bowel disease: a systematic review and meta-analysis. *Carmen Andalucia, Chelsea Bentow, Laura Martinez-Prat, Michael P. Horn, Michael Mahler (San Diego, USA)*

**C16** Tales of the unexpected. Selective IgA deficiency unravelled by Gluten Free Diet. *Angel López Brull, Elena Sancho Cadenas, Natalia Casado Navarro, Marian Dávila Rosales, María Rosé Martínez-Becerra (Madrid, Spain)*

**C17** Temperature, PH dependency and activity of microbial transglutaminase and its gliadin cross-linked neo-complexes. *Torsten Matthias, Patricia Wusterhausen, Ramesh Ajay (Wendelsheim, Germany)*

**C18** Generation of monoclonal antibodies against tTG and mTG neo epitopes. *Torsten Matthias, Ramesh Ajay (Wendelsheim, Germany)*

- C19** First multiparametric point of care test for gluten related disorders. *Torsten Matthias, Aliaksei Shymanets, Patricia Wusterhausen, Jennifer Orth (Wendelsheim, Germany)*
- C20** Method comparison of two calprotectin immunoassays: the EliA™ Calprotectin 2 test (Thermo Fisher Scientific) and CALiaGold® (Sentinel Diagnostics). *Edith Vermeulen, L. Pouillon, S. van Aelst, A. Sierens, M. van Blerk, I. Geerts, P. Bossuyt Bossuyt (Bonheiden, Belgium)*
- C21** The comparison and optimization of calprotectin extraction in routine IBD care. *Edith Vermeulen, L. Pouillon, B. Possemiers, A. Goovaerts, I. Geerts, P. Bossuyt (Bonheiden, Belgium)*
- C22** Retrospective analysis of different diagnostic procedures for diagnosis of pediatric coeliac disease in a local German study. *Johannes Wolf, Christin Goldhardt, Marlen Zurek, Stephan Borte (Leipzig, Germany)*
- C23** F-actin as a new marker antigen on an established multiparametric immunoassay profile for liver diseases. *Andrea Deerberg, Antonina Ott, Marco Kai, Thomas Scheper, Wolfgang Meyer (Lübeck, Germany)*
- C24** Concordance of the results of antimitochondrial antibodies (AMA) testing with immunofluorescence on rodent tissue sections and line immunoassay. *Andrea Tesija Kuna, Milena Hanzek, Ines Vukasovic, Valentina Veric, Tamara Susic (Zagreb, Croatia)*
- C25** Novel fully automated anti-GAD65 autoantibodies immunoassay: technical comparison to ELISA and CLIA reveals different sensitivities. *Daniel Filchtinski, Johannes Schulte-Pelkum (Freiburg Germany)*
- C26** Serum levels of anti-elastin and anti-fibrillin 1 autoantibodies in recurrent pregnancy loss (RPL) patients. *Milena Atanasova, E. Konova, S. Blazeva, T. Bodurska (Pleven, Bulgaria)*
- C27** Retrospective evaluation of “Rings and Rods” pattern detected in the anti-nuclear antibody (ANA) indirect immunofluorescence (IIF) test. *Neşe İnal, Berke Kurumanastirli, Tutku Taskinoglu, Alev Çetin Duran, Alper Togay, Fatma Mutlu Sarıguzel, Nilgün Kasifoglu, Mehmet Soylu, Yavuz Dogan, Ebru Us, Zeynep Sarıbas, Nese Kaklıkkaya, Burçin Sener (Ankara, Turkey)*
- C28** Bone mineral density in patients with alkaptonuria. *Elizabeth Záhová, D. Kozáková, R. Imrich Piešťany, Slovakia)*
- C29** Humoral response to SARS-Cov-2: a perspective study in vaccinated subjects and COVID19 patients. *Piera De Gaspari, Piero Novel, Enrico Favaro, Lisa Agatea (Padova, Italy)*
- C30** Severe acute respiratory syndrome coronavirus-2 variants and antibody responses in Bangladesh. *Asish Kumar Ghosh, Marco Kaiser, Olfert Landt, Simon D. Lytton (Munich, Germany)*
- C31** Evidence of the presence of antinuclear antibodies (ANA) in healthcare workers after mRNA based anti-SARS-CoV-2 vaccines: two years follow-up study. *Maria Christina Sacchi, C. Pelazza, L. Agatea, P. De Gaspari, M. Bertolotti, D. Ielo, P. Stobbione, M. Grappiolo, T. Bolgeo, P. Novel, A. Maconi, M.M. Ciriello (Alessandria, Italy)*
- C32** Prediction of the occurrence of neutralizing antibodies for SARS-CoV-2 according to the titer of anti-Spike IgG antibodies after vaccination. *Ines Vukasović, Milena Hanžek, Lara Milevoj Kopčinović, Andrea Tešija Kuna Andrea, Nora Nikolac Gabaj (Zagreb, Croatia)*

## GENERAL INFORMATION

<b>Chairman</b>	Karsten Conrad, Germany
<b>Co-Chairmen</b>	Luis E.C. Andrade, Brazil Marvin Fritzer, Canada Edward K.L. Chan, USA Jan Damoiseaux, The Netherlands Pier Luigi Meroni, Italy Ger J. M. Pruijn, The Netherlands Günter Steiner, Austria
<b>Honorary Chair</b>	Yehuda Shoenfeld, Israel
<b>International Advisory Board</b>	Martin Aringer, Germany Martin Blüthner, Germany Dimitrios P. Bogdanos, Greece Xavier Bossuyt, Belgium Carlos A. Casiano, USA Manfred Herold, Austria Maria Infantino, Italy Christian Moritz, France Carlos Alberto von Mühlen, Brazil Johan Rönnelid, Sweden
<b>Industrial Board</b>	Lars Komorowski, EUROIMMUN Medizinische Labordiagnostika AG Michael Mahler, Werfen Nina Olschowka, Phadia GmbH ThermoFisher Scientific Dirk Roggenbuck, GA Generic Assays GmbH
<b>National Organizing Committee</b>	Rico Hiemann Thorsten Krieger Dirk Reinhold Ulrich Sack Werner Schößler Clemens August Schulze Lohoff (Members of the Advisory Committee of the GFID e.V.)